Leveraging Transcriptional Control to Find New Targeted Drugs for Pediatric Cancers - Enduring
New research techniques have been applied to studying pediatric cancers, allowing a deeper understanding of their biology and the associated therapeutic implications. As science progresses, it is imperative to stay updated in order to close the gap between current and ideal practice.
Pediatric cancers are often genomically quiet, so relying on sequencing to find "druggable" targets has not yet led to breakthroughs in many pediatric cancers. Understanding the impact of chromatin modifications on pediatric cancer gene expression is an emerging field. This activity will update the audience on how knowledge of the transcriptional landscape may have translational benefit for pediatric cancers, including leukemia.
Pediatric hematology/oncology physicians, nurses, nurse practitioners, clinical research, and social workers.
- Define a super-enhancer and the expected effect on the transcription of the gene it controls.
- Describe the relevance of retinoid signaling in non-APL pediatric AML.
- State the response rates of EZH2 inhibitors in children and young adults with rhabdoid tumors and what future trials will be studying.
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Joanna Yi has indicated she has nothing to disclose.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
This activity will included a discussion of the off-label or investigational use of Tazemetostat and Tamibarotene.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
Leveraging Transcriptional Control to Find New Targeted Drugs for Pediatric Cancers has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Leveraging Transcriptional Control to Find New Targeted Drugs for Pediatric Cancers - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance